Former Interim President and Chief Executive Officer · Fulcrum Therapeutics, Inc. (FULC)

Robert Gould

A named executive officer of Fulcrum Therapeutics in every fiscal year CompBrief holds from FY2018 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$424,501

Salary $300,000Stock awards $0

FY2022: $118,342

6th of 6 named executive officers at Fulcrum Therapeutics by FY2023 total.

6 named officers on file for Fulcrum Therapeutics, FY2023

Robert Gould’s pay file — $29

  • 6 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Fulcrum Therapeutics’s whole pay program stands against its peers

  • Fulcrum Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on FULC→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 19, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Robert Gould’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Robert Gould compensation by year

Fulcrum Therapeutics Summary Compensation Table · all 6 fiscal years held
In US dollars, as Fulcrum Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019FY2020FY2021FY2022FY2023
Salary$442,900$478,195$535,000$167,681$0$300,000
Bonus$203,734$300,000$240,750—$0$0
Stock awards$207,000$0$0$0$0$0
Option awards$0$3,111,158$2,240,600$2,174,058$73,342$76,404
Non-equity incentive$0$0$0$0$0$0
Pension and deferred compensation$0$0$0$0$0$0
All other$0$0$0$0$45,000$48,097
Total$853,634$3,889,353$3,016,350$2,341,739$118,342$424,501

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Fulcrum Therapeutics, Inc. DEF 14A filed April 19, 2024, accession 0001193125-24-102863, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Fulcrum Therapeutics, Inc. filed document, accession 0001193125-24-102863. Every figure is read from that document and cited to the page and table it appears in. Filed April 19, 2024.

$854K
$3.9M
$3.0M
$2.3M
$118K
$425K
FY18
FY19
FY20
FY21
FY22
FY23
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option12,500—$16.87
Option30,000—$3.16
Option84,184—$11.33

Per the Outstanding Equity Awards at Fiscal Year-End table in Fulcrum Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

7 Form 4 lines since the FY2023 proxy (filed April 19, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-06-30Grant or award derivative—32,000$0.0032,000
2026-02-02Sale—15,000$10.72454,864
2026-01-02Sale—15,000$10.87469,864
2026-01-02Sale—15,000$11.87469,864
2025-11-19Sale—15,000$11.03484,864
2025-06-26Grant or award derivative—36,000$0.0036,000
2024-06-17Grant or award derivative—30,000$0.0030,000

The 7 most recent of 7 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Fulcrum Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Alex SapirPresident and Chief Executive Officer$6,990,596
Curtis OltmansChief Legal Officer$2,319,661
Mel HayesExecutive Vice President, Patient Affairs$2,192,854
Alan MussoChief Financial Officer$1,879,833
Bryan StuartFormer President and Chief Executive Officer$1,869,696
Robert Gould · this pageFormer Interim President and Chief Executive Officer$424,501

Board service

Fulcrum Therapeutics board · FY2022–FY2025
Director compensation in US dollars, as Fulcrum Therapeutics reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$50,000—$219,406—$269,406
FY2024$50,000$0$167,559$0$217,559
FY2023—————
FY2022$45,000—$73,342—$118,342

Each year as the company reported it in Fulcrum Therapeutics's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Fulcrum Therapeutics pays directors a $40,000 cash retainer. As stated in Fulcrum Therapeutics's FY2025 proxy.

Committees

Science and Technology (Chair)

The full Fulcrum Therapeutics compensation record

free company brief

This page is one person within Fulcrum Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Fulcrum Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Robert Gould's compensation dossier · One-time report. No refunds.